Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LipLong: BAY79-4980 vs rFVIII-FS in Hemophilia A
NCT00623727Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jun 2008
- Primary completion
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 26
01
Overview
A Phase 2 trial of BAY 79-4980 in hemophilia A, sponsored by Bayer. Started Jun 2008; status: terminated.
02
Drugs
BAY 79-4980
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00623727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623727.